Experimental model shows TGF-β1-modified MSCs improve wound healing, suggesting potential for therapy.
Human mesenchymal stem cells (MSCs) are a promising stem cell source; however, their therapeutic efficacy in chronic wound healing remains limited. This study evaluates the therapeutic potential of transforming growth factor (TGF)-β1-modified, three-dimensionally cultured MSCs (A/T-3D) for enhancing wound healing. Methods: The TGF-β1 gene was inserted into a safe genomic locus in adipose-derived MSCs (ASCs) using transcription activator-like effector nucleases. Quantitative polymerase chain reaction (qPCR) analysis showed that A/T-3D upregulated key factors related to wound healing, including epidermal growth factor (EGF), TGF-β1, fibroblast growth factor (FGF), and vascular endothelial growth factor (VEGF)-A, compared to unmodified ASCs. Results: In vitro scratch wound assays indicated that co-culture with A/T-3D-conditioned medium significantly accelerated wound closure in fibroblasts. In vivo, skin excision in nude mice treated with A/T-3D injections resulted in rapid wound closure, enhanced cellularity, and increased reepithelialization. High engraftment rates of A/T-3D and elevated expression of angiogenic factors were observed in the wound bed, highlighting their direct contribution to tissue repair. Conclusions: Collectively, these findings suggest that A/T-3D MSCs have significant therapeutic potential for wound healing through the secretion of epithelialization and angiogenic factors, along with enhanced engraftment capacity.
No takes yet. Share an insight, caveat, or question.
Chae et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: